ARTO试验:SBRT联合阿比特龙及ADT治疗寡转移去势抵抗性前列腺癌的长期总生存分析
ARTO是一项多中心、开放标签、随机2期试验,纳入157例寡转移去势抵抗性前列腺癌患者,比较ADT+阿比特龙联合或不联合SBRT(针对所有转移灶)的疗效。结论:在系统治疗基础上加用转移灶定向放疗可显著改善总生存。
要点
- 在ADT+阿比特龙基础上联合SBRT可显著延长寡转移CRPC患者的总生存。
- 3-4级不良事件主要为感染和心血管事件,组间总体可控。
核心结论
- 在寡转移去势抵抗性前列腺癌患者中,于ADT+阿比特龙基础上加用SBRT可显著改善总生存。
研究设计与样本
- ARTO为多中心、开放标签、随机2期试验,在意大利16个中心开展,纳入157例患者。
- 患者按1:1随机分配至对照组(n=82)或实验组(n=75),实验组接受SBRT(1-5次,生物有效剂量≥100 Gy)联合ADT+阿比特龙。
- 主要终点为6个月生化反应(PSA较基线下降≥50%),本次为预设外长期随访的总生存分析。
主要发现
- 最常见的3-4级不良事件为感染性并发症(对照组5例 vs 实验组0例)和心血管疾病(对照组3例 vs 实验组3例)。
- 对照组发生1例治疗相关死亡(心肌衰竭)。
关键数值与推荐
- 入组标准:年龄≥18岁,前列腺腺癌,去势抵抗性转移性前列腺癌,转移灶≤3个,未接受过针对CRPC的系统治疗。
- SBRT剂量:1-5次,生物有效剂量≥100 Gy,照射所有转移灶。
临床怎么用
- 对于寡转移性去势抵抗性前列腺癌患者,可考虑在ADT+阿比特龙基础上联合SBRT照射所有转移灶以改善总生存。
- 治疗决策时需评估感染和心血管风险,并监测相关不良事件。
局限性
- 本次分析为预设外长期随访,统计效能更新为事后进行。
- 试验为2期、开放标签设计,样本量有限(157例)。
- 未收集种族或民族数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer. The aim of this analysis is to explore the long-term impact of MDT on overall survival. METHODS: ARTO was a multicentre, phase 2, randomised trial conducted in 16 academic and community centres across Italy. All patients included were aged 18 years or older and had a diagnosis of prostate adenocarcinoma with metastatic castrate-resistant prostate cancer, no more than three metastatic sites, and no previous systemic therapy for metastatic castrate-resistant prostate cancer status. Patients were randomly assigned (1:1, using random permuted blocks; stratified by treating centre, Eastern Cooperative Oncology Group performance status, and number of metastases) in an open-label design to androgen deprivation therapy plus oral abiraterone acetate 1000 mg daily with or without SBRT to all sites of metastatic disease (one to five fractions providing a biologically effective dose ≥100 Gy). The primary endpoint was 6-month biochemical response (PSA decrease of ≥50% compared with baseline) and has been reported previously. After meeting its primary endpoint, the power calculation was updated post-hoc to assess overall survival, finalised before data unmasking. We present an unplanned long-term follow-up focusing on overall survival. All analyses were performed on an intention-to-treat basis. The trial is registered on ClinicalTrials.gov (NCT03449719) and is now closed. FINDINGS: Between Jan 2, 2019, and Sept 7, 2022, 157 patients were randomly assigned to the control (n=82) and experimental (n=75) groups. No data about race or ethnicity were collected. After a median follow up of 53 months (IQR 43-60), median overall survival was 50 months (95% CI 36-not reached [NR]) in the control group versus NR (55-NR) in the experimental group (HR 0·55, 95% CI 0·33-0·92, p=0·021). Most common grade 3-4 adverse events recorded were infectious complications (five in the control group vs zero in the experimental group) and cardiovascular disorders (three in the control group vs three in the experimental group). One treatment-related death occurred in the control group due to myocardial failure. INTERPRETATION: The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone. FUNDING: Fondazione Radioterapia Oncologica.
引用
- Francolini G, Di Cataldo V, Caini S, et al. SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial. Lancet Oncol. 2026. PMID: 42372744. doi:10.1016/S1470-2045(26)00178-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。